Recent News

• 09.02.2025 - Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
• 08.18.2025 - Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
• 08.04.2025 - Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
• 06.24.2025 - Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
• 06.23.2025 - Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Recent Filings

• 08.20.2025 - 8-K Current report
• 08.18.2025 - 8-K Current report
• 08.15.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - RW Registration Withdrawal Request
• 08.04.2025 - EX-99.1 EX-99.1
• 08.04.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 08.04.2025 - 8-K Current report
• 07.16.2025 - DEF 14A Other definitive proxy statements
• 07.16.2025 - ARS Annual Report to Security Holders